Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Status:
RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of -synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Phase:
PHASE2
Details
Lead Sponsor:
Tanta University
Collaborators:
Dr. Raed Ahmed Abdel-Maboud,Lecturer of neurology,Faculty of Medicine,Tanta University Prof. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University